Amgen unveils its KRas inhibitor in human clinical trials
Wednesday, April 3, 2019 - 13:10
in Health & Medicine
AMG 510 shuts down a mutant version of the cancer target via covalent interaction
AMG 510 shuts down a mutant version of the cancer target via covalent interaction